


# China's biotech: From Fast-Follow to First-in-Class



# Weekly Facts & Figures.

- **Global assets:** Chinese biotech is delivering assets that attract major pharma.
- **Faster reviews:** NMPA may cut trial review times to 30 days.
- **New markets:** Firms expand into Southeast Asia, the Middle East, and Latin America.

# What This Means.

China's 'DeepSeek moment' in biotech did not come out of nowhere — it is the payoff from a decade of patient, systemic investment in talent, regulation, and industry maturity.



**Jingwen Tong**  
Director



**Follow us & activate the bell to never miss  
a Sinolytics Radar again!**



**Discover more insights and services:  
Visit [www.sinolytics.de](http://www.sinolytics.de)**